Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.

Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.

Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.

Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.

Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.

Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.

Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.

Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.

In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.

Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.